Advances in effects of cannabinoid receptor type 1 on drug-induced cardiotoxicity

doi:10.3969/j.issn.1674-8115.2025.12.016

Abstract

Abstract:

Drug-induced cardiotoxicity, as a major global public health challenge, has led to substantial consumption of medical resources and significant economic losses. Recent studies have revealed that the cannabinoid type 1 receptor (CB1R) plays an important role in various types of drug-induced cardiac injury. This article systematically reviews the molecular characteristics of CB1R and its dual roles in cardiovascular physiology and pathophysiology, with a focus on its molecular mechanisms in cardiotoxicity induced by antipsychotics, anticancer drugs, cannabis, and synthetic cannabinoids. As a key component of the endocannabinoid system, CB1R is widely distributed in cardiomyocytes, endothelial cells, and immune cells. Under normal physiological conditions, it contributes to the homeostatic regulation of heart rate, blood pressure, and cardiovascular contractile activity. It participates in pathological processes, including cardiac electrophysiological disturbances, inflammatory responses, and myocardial fibrosis, through modulation of ion channel activity, release of inflammatory factors, and oxidative/nitrative stress. It is also involved in the mechanisms underlying drug-induced cardiotoxicity. CB1R represents a common pathway in the cardiotoxicity of multiple drugs and may become an important target for the prevention and treatment of drug-induced cardiotoxicity. Future research needs to further elucidate the regulatory mechanisms of CB1R under different pathological conditions and explore precise interventions targeting CB1R to balance therapeutic benefits of drugs against cardiovascular risks.

Key words: cardiotoxicity, cannabinoid receptor, antipsychotic, anti-cancer drug, marijuana, synthetic cannabinoid

CLC Number:

BO Yiming, CUI Qinghuan, LI Liliang. Advances in effects of cannabinoid receptor type 1 on drug-induced cardiotoxicity[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(12): 1694-1700.

Figures/Tables 2

TrendMD

References 60

[1]	KUNDNANI N R, PASSINI V, STEFANIA CARLOGEA I, et al. Overview of oncology: drug-induced cardiac toxicity[J]. Medicina (Kaunas), 2025, 61(4): 709.
[2]	MAMOSHINA P, RODRIGUEZ B, BUENO-OROVIO A. Toward a broader view of mechanisms of drug cardiotoxicity[J]. Cell Rep Med, 2021, 2(3): 100216.
[3]	HOWELL S, YAROVOVA E, KHWANDA A, et al. Cardiovascular effects of psychotic illnesses and antipsychotic therapy[J]. Heart, 2019, 105(24): 1852-1859.
[4]	LI X Q, TANG X R, LI L L. Antipsychotics cardiotoxicity: what's known and what's next[J]. World J Psychiatry, 2021, 11(10): 736-753.
[5]	DEMPKE W C M, ZIELINSKI R, WINKLER C, et al. Anthracycline-induced cardiotoxicity: are we about to clear this hurdle?[J]. Eur J Cancer, 2023, 185: 94-104.
[6]	NIELSEN R E, BANNER J, JENSEN S E. Cardiovascular disease in patients with severe mental illness[J]. Nat Rev Cardiol, 2021, 18(2): 136-145.
[7]	COPPOLA C, RIENZO A, PISCOPO G, et al. Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs[J]. Cancer Treat Rev, 2018, 63: 135-143.
[8]	HERRMANN J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia[J]. Nat Rev Cardiol, 2020, 17(8): 474-502.
[9]	CROCQ M A. History of cannabis and the endocannabinoid system[J]. Dialogues Clin Neurosci, 2020, 22(3): 223-228.
[10]	AN D C, PEIGNEUR S, HENDRICKX L A, et al. Targeting cannabinoid receptors: current status and prospects of natural products[J]. Int J Mol Sci, 2020, 21(14): 5064.
[11]	WEI F M, ZHAO L, JING Y H. Signaling molecules targeting cannabinoid receptors: hemopressin and related peptides[J]. Neuropeptides, 2020, 79: 101998.
[12]	REN S Y, WANG Z Z, ZHANG Y, et al. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors[J]. Acta Pharmacol Sin, 2020, 41(10): 1263-1271.
[13]	HOWLETT A C, ABOOD M E. CB₁ and CB₂ receptor pharmacology[J]. Adv Pharmacol, 2017, 80: 169-206.
[14]	TIAN N, YANG C, DU Y, et al. Cannabinoid receptor 2 selective agonist ameliorates adjuvant-induced arthritis by modulating the balance between Treg and Th17 cells[J]. Front Pharmacol, 2025, 16: 1532518.
[15]	YE L Y, CAO Z, WANG W W, et al. New insights in cannabinoid receptor structure and signaling[J]. Curr Mol Pharmacol, 2019, 12(3): 239-248.
[16]	NIEDERHOFFER N, SCHMID K, SZABO B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression[J]. Naunyn Schmiedebergs Arch Pharmacol, 2003, 367(5): 434-443.
[17]	IBRAHIM B M, ABDEL-RAHMAN A A. Role of brainstem GABAergic signaling in central cannabinoid receptor evoked sympathoexcitation and pressor responses in conscious rats[J]. Brain Res, 2011, 1414: 1-9.
[18]	YAO F R, ABDEL-RAHMAN A A. Estrogen dampens central cannabinoid receptor 1-mediated neuroexcitation and pressor response in conscious female rats[J]. Biochem Pharmacol, 2022, 201: 115102.
[19]	LAGATTA D C, FASSINI A, TERZIAN A L, et al. The medial prefrontal cortex and the cardiac baroreflex activity: physiological and pathological implications[J]. Pflugers Arch, 2023, 475(3): 291-307.
[20]	PACHER P, NAGAYAMA T, MUKHOPADHYAY P, et al. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats[J]. Nat Protoc, 2008, 3(9): 1422-1434.
[21]	AL KURY L T, VOITYCHUK O I, YANG K S, et al. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes[J]. Br J Pharmacol, 2014, 171(14): 3485-3498.
[22]	WANG L N, XING M D, QU W T, et al. Impaired vessel relaxation response and increased infarct size in smooth muscle cannabinoid receptor 1 knockout mice[J]. Microvasc Res, 2022, 139: 104263.
[23]	SCHAICH C L, SHALTOUT H A, BROSNIHAN K B, et al. Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats[J]. Physiol Rep, 2014, 2(8): e12108.
[24]	BLADEN C, MIRLOHI S, SANTIAGO M, et al. Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro[J]. Neuropharmacology, 2021, 187: 108478.
[25]	WERESA J, PĘDZIŃSKA-BETIUK A, MIŃCZUK K, et al. Why do marijuana and synthetic cannabimimetics induce acute myocardial infarction in healthy young people?[J]. Cells, 2022, 11(7): 1142.
[26]	RICHARDS J R. Mechanisms for the risk of acute coronary syndrome and arrhythmia associated with phytogenic and synthetic cannabinoid use[J]. J Cardiovasc Pharmacol Ther, 2020, 25(6): 508-522.
[27]	MAGGO S, ASHTON J C. Effect of cannabinoid receptor agonists on isolated rat atria[J]. J Cardiovasc Pharmacol, 2018, 72(4): 191-194.
[28]	DOL-GLEIZES F, PAUMELLE R, VISENTIN V, et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2009, 29(1): 12-18.
[29]	RAJESH M, BÁTKAI S, KECHRID M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy[J]. Diabetes, 2012, 61(3): 716-727.
[30]	HOHMANN A G, SUPLITA R L, BOLTON N M, et al. An endocannabinoid mechanism for stress-induced analgesia[J]. Nature, 2005, 435(7045): 1108-1112.
[31]	WANG F L, YUAN Q H, CHEN F Y, et al. Fundamental mechanisms of the cell death caused by nitrosative stress[J]. Front Cell Dev Biol, 2021, 9: 742483.
[32]	MUKHOPADHYAY P, RAJESH M, BÁTKAI S, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes[J]. Cardiovasc Res, 2010, 85(4): 773-784.
[33]	LI L L, GAO P, TANG X R, et al. CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity[J]. Signal Transduct Target Ther, 2022, 7(1): 190.
[34]	SLAVIC S, LAUER D, SOMMERFELD M, et al. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome[J]. J Mol Med (Berl), 2013, 91(7): 811-823.
[35]	WAGNER J A, HU K, KARCHER J, et al. CB₁ cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction[J]. Br J Pharmacol, 2003, 138(7): 1251-1258.
[36]	LU Y, AKINWUMI B C, SHAO Z J, et al. Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes[J]. J Cardiovasc Pharmacol, 2014, 64(5): 420-430.
[37]	RAY W A, CHUNG C P, MURRAY K T, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death[J]. N Engl J Med, 2009, 360(3): 225-235.
[38]	SUN D M, LI L L, ZHANG X, et al. Causes of sudden unexpected death in schizophrenia patients: a forensic autopsy population study[J]. Am J Forensic Med Pathol, 2019, 40(4): 312-317.
[39]	HE L Y, YU Y M, WEI Y M, et al. Characteristics and spectrum of cardiotoxicity induced by various antipsychotics: a real-world study from 2015 to 2020 based on FAERS[J]. Front Pharmacol, 2022, 12: 815151.
[40]	ARZUK E, KARAKUŞ F, ORHAN H. Bioactivation of clozapine by mitochondria of the murine heart: possible cause of cardiotoxicity[J]. Toxicology, 2021, 447: 152628.
[41]	PATEL J J, LISI P A, LATHARA Z, et al. Clozapine-induced peripheral and pleural fluid eosinophilia[J]. Ann Pharmacother, 2012, 46(2): e4.
[42]	WANG J F, MIN J Y, HAMPTON T G, et al. Clozapine-induced myocarditis: role of catecholamines in a murine model[J]. Eur J Pharmacol, 2008, 592(1/2/3): 123-127.
[43]	LI L L, DONG X R, TU C Y, et al. Opposite effects of cannabinoid CB₁ and CB₂ receptors on antipsychotic clozapine-induced cardiotoxicity[J]. Br J Pharmacol, 2019, 176(7): 890-905.
[44]	LI X Q, PENG Z, ZHOU Y L, et al. Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors[J]. Toxicol Lett, 2019, 313: 77-90.
[45]	IJAZ S, BOLEA B, DAVIES S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews[J]. BMC Psychiatry, 2018, 18(1): 275.
[46]	RAWAT P S, JAISWAL A, KHURANA A, et al. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management[J]. Biomed Pharmacother, 2021, 139: 111708.
[47]	ZHANG S, LIU X B, BAWA-KHALFE T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18(11): 1639-1642.
[48]	MUKHOPADHYAY P, BÁTKAI S, RAJESH M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity[J]. Am Coll Cardiol, 2007, 50(6): 528-536.
[49]	MUKHOPADHYAY P, HORVÁTH B, RAJESH M, et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury[J]. Free Radic Biol Med, 2011, 50(1): 179-195.
[50]	HALL W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?[J]. Addiction, 2015, 110(1): 19-35.
[51]	HOCH E, VOLKOW N D, FRIEMEL C M, et al. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits[J]. Eur Arch Psychiatry Clin Neurosci, 2025, 275(2): 281-292.
[52]	COTIER P, MAYER C, ETTING I, et al. Evaluation of the cardiovascular risk induced by cannabis use from a series of 43 autopsy cases[J]. Int J Legal Med, 2023, 137(6): 1725-1733.
[53]	GORELICK D A, HEISHMAN S J, PRESTON K L, et al. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers[J]. Am Heart J, 2006, 151(3): 754.e1-754.e5.
[54]	CHANDY M, NISHIGA M, WEI T T, et al. Adverse impact of cannabis on human health[J]. Annu Rev Med, 2024, 75: 353-367.
[55]	WEI T T, CHANDY M, NISHIGA M, et al. Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation[J]. Cell, 2022, 185(10): 1676-1693.e23.
[56]	SHETE V, MAHAJAN N M, SHIVHARE R, et al. Genistein: a promising phytoconstituent with reference to its bioactivities[J]. Phytother Res, 2024, 38(8): 3935-3953.
[57]	FENG X J, XU S W, WENG J P. Marijuana and endothelial dysfunction: new mechanism and therapy[J]. Trends Mol Med, 2022, 28(8): 613-615.
[58]	OLIVEIRA N M C, MACHADO D A, DA SILVA T L, et al. Treatment with cannabidiol results in an antioxidant and cardioprotective effect in several pathophysiologies[J]. Curr Hypertens Rev, 2022, 18(2): 125-129.
[59]	GIOÉ-GALLO C, ORTIGUEIRA S, BREA J, et al. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs[J]. Biomed Pharmacother, 2023, 164: 114934.
[60]	MASLOV L N, LASUKOVA O V, KRYLATOV A V, et al. Selective cannabinoid receptor agonist HU-210 decreases pump function of isolated perfused heart: role of cAMP and cGMP[J]. Bull Exp Biol Med, 2004, 138(6): 550-553.